HomeMarketsSharesIntuitive Surgical, Inc.

Trade Intuitive Surgical, Inc. - ISRG CFD

Market is not available at the momentMarket information is presented
as of 2026-10-16T19:46:06+00:00
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.44
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.02224 %
(-$4.45)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


-0.02224%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
0.00001 %
($0.00)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


0.00001%
Overnight funding adjustment time21:00 (UTC)
CurrencyUSD
Min traded quantity0.1
Margin5.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close427.7
Open429.07
1-Year Change-1.38%
Day's Range425.64 - 433.38

Trade Intuitive Surgical, Inc. - ISRG

Intuitive Surgical, Inc. (ISRG) is a developer of minimally invasive, robot-assisted surgery. The company develops, manufactures and markets the da Vinci surgical system.

Established in 1995, Intuitive is headquartered in California and operates across the US, Western Europe, and the Asia Pacific regions. It also operates in China through Intuitive Fosun, a joint venture with Fosun Pharma.

The da Vinci Surgical System helps physicians and healthcare providers conduct complex surgery with the help of robots. The process reduces variability in surgery, and helps deliver better care and early recovery.

Intuitive also designed and developed Ion, a robot-assisted endoluminal platform. Ion is designed to perform peripheral lung biopsies with the help of an advanced ultra-thin, ultra-manoeuvrable catheter that allows navigation far into the peripheral lung. The technology is precise and gives unprecedented stability. 

Along with the launch of the da Vinci surgical system, Intuitive Surgical went public in 2000, trading on the Nasdaq stock exchange under the ticker symbol ISRG.

Check out ISRG’s price history and today’s quote, and follow the ups and downs of the share value at Capital.com. Stay on top of the latest price developments with our live ISRG stock chart.

Latest shares articles

BAE Systems stock forecast
BAE Systems stock forecast: H1 results, guidance upgrade
BAE Systems is a UK defence and aerospace group listed in London. In August 2026, it secured a $149.8m US Navy award for work on the USS Boxer. Explore third-party BA. price targets and technical analysis. Past performance is not a reliable indicator of future results.
07:18, 16 October 2026
TAURON stock forecast
TAURON stock forecast: H1 earnings
TAURON is a Polish energy group. In the first half of 2026, revenue was broadly flat, while EBITDA and net profit fell amid higher CO2 allowance costs and coal consumption. Explore third-party analyst targets and technicals. Past performance is not a reliable indicator of future results.
12:04, 12 October 2026
Puma stock forecast
Puma stock forecast: Anta stake deal cleared
Puma is a German sportswear company. Chinese regulators have cleared Anta Sports’ proposed acquisition of an approximately 29% stake, with completion expected before the end of 2026. Explore third-party PUM price targets. Past performance is not a reliable indicator of future results.
10:19, 12 October 2026
Dino Polska stock forecast
Dino Polska stock forecast: H1 sales growth slows
Dino Polska is a Polish grocery retailer. In H1 2026, revenue rose 12.5% year on year to 18.0bn PLN, while like-for-like sales growth slowed to 2.2%. Explore third-party DNP price targets and technical analysis. Past performance is not a reliable indicator of future results.
08:27, 12 October 2026

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready